The past, present and future of HIV-vaccine development: a critical view. (Q30329411)

18 June 2017

1 reference

title

The past, present and future of HIV-vaccine development: a critical view. (English)

1 reference

18 June 2017

Alexandra Bojak

1

1 reference

18 June 2017

Ludwig Deml

series ordinal

2

1 reference

18 June 2017

Ralf Wagner

series ordinal

3

1 reference

18 June 2017

publication date

1 January 2002

1 reference

18 June 2017

1 reference

18 June 2017

volume

7

1 reference

18 June 2017

issue

1

1 reference

18 June 2017

page(s)

36-46

1 reference

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

18 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Correlates of protection in HIV infection and the progression of HIV infection to AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

In vitro correlates of HIV-2-mediated HIV-1 protection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

The immunological principles of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

A vaccine for HIV type 1: the antibody perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Antibody and virus: binding and neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Endosomal proteases and antigen processing

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4+ T Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

The importance of the innate immune system in controlling HIV infection and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

The nature of the principal type 1 interferon-producing cells in human blood

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Lymphoid organs function as major reservoirs for human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Reservoirs of HIV infection or carriage: monocytic, dendritic, follicular dendritic, and B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Fine-specificity of cytotoxic T lymphocytes which recognize conserved epitopes of the Gag protein of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Construction of attenuated HIV-1 accessory gene immunization cassettes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

HIV-1 Tat protein as a potential AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

1 reference

7 January 2021

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Codon usage limitation in the expression of HIV-1 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Applications of pox virus vectors to vaccination: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

NYVAC: a highly attenuated strain of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Nonreplicating vaccinia vector efficiently expresses recombinant genes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV inf

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Induction of mucosal and systemic responses against human immunodeficiency virus type 1 glycoprotein 120 in mice after oral immunization with a single dose of a Salmonella-HIV vector

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902081-5

7 January 2021

10.1016/S1359-6446(01)02081-5

Identifiers

DOI

1 reference

18 June 2017

1 reference